HomeCompareGBT vs ADC

GBT vs ADC: Dividend Comparison 2026

GBT yields 2.92% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $154.9K in total portfolio value· pulled ahead in Year 2
10 years
GBT
GBT
● Live price
2.92%
Share price
$68.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.1K
Annual income
$352.49
Full GBT calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — GBT vs ADC

📍 ADC pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBTADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBT + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBT pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBT
Annual income on $10K today (after 15% tax)
$248.21/yr
After 10yr DRIP, annual income (after tax)
$299.62/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,378.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBT + ADC for your $10,000?

GBT: 50%ADC: 50%
100% ADC50/50100% GBT
Portfolio after 10yr
$101.5K
Annual income
$40,574.89/yr
Blended yield
39.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

GBT
Analyst Ratings
18
Buy
11
Hold
Consensus: Buy
Price Target
$60.38
-11.8% upside vs current
Range: $36.00 — $110.00
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBT buys
0
ADC buys
0
No recent congressional trades found for GBT or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBTADC
Forward yield2.92%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$24.1K$178.9K
Annual income after 10y$352.49$80,797.29
Total dividends collected$3.2K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$60.38$81.06

Year-by-year: GBT vs ADC ($10,000, DRIP)

YearGBT PortfolioGBT Income/yrADC PortfolioADC Income/yrGap
1$10,992$292.01$10,990$580.36+$2.00GBT
2← crossover$12,061$299.98$12,301$860.26$240.00ADC
3$13,213$307.63$14,104$1,298.62$891.00ADC
4$14,453$314.97$16,691$2,008.16$2.2KADC
5$15,787$321.98$20,580$3,205.09$4.8KADC
6$17,221$328.69$26,754$5,330.02$9.5KADC
7$18,761$335.08$37,196$9,345.14$18.4KADC
8$20,416$341.18$56,244$17,523.09$35.8KADC
9$22,192$346.98$94,286$35,736.21$72.1KADC
10$24,098$352.49$178,949$80,797.29$154.9KADC

GBT vs ADC: Complete Analysis 2026

GBTStock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Full GBT Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this GBT vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBT vs SCHDGBT vs JEPIGBT vs OGBT vs KOGBT vs MAINGBT vs NNNGBT vs EPRTGBT vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.